Focus: Skyhawk Therapeutics is a public-stage biotechnology company focused on RNA-correcting small molecules for gene therapy applications. The company is headquartered in Waltham, MA and operates at the cutting edge of RNA therapeutic modalities.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Best suited for scientists and clinicians willing to bet on novel modality upside in exchange for higher execution risk and limited current scale.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Skyhawk Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Skyhawk Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo